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Abstract: Restenosis remains a major limitation of corortary 
angioplasty in spite of major advances in techniques and tech- 
nology. Recent studies have demonstrated that ionizing 
radiation may limit the degree of this problem. Gamma radia- 
tion has been shown to be effective in reducing in stent reste- 
nosis in humans, and beta radiatio~ following encouraging 
results in animals has been shown to be feasible in humans. 
The objective of this study was to assess the feasibility of a 5 F 
non-centered catheter to deliver beta radiation emitting seeds 
to the lesion site post angioptasty and its effect on restenosis. 
Following successful angioplasty, patients were randomized 
to treatment with 12.14 or 16 Gy at the angioplasty site. This 
was delivered with a 5 t" non-centered catheter. Twelve beta 
radiation emittfi~g seeds (g~ were delivered to an ama 
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3 cm in length to cover the angioplasty site. Angiographic fol- 
Iow-up was performed at 6 months. Baseline and follow-up 
angiograms were performed by blinded investigators at a 
core laboratory. 
This interim report comprises the first 35 patients to complete 
6-month angiographic follow-up. Thme were no major radia- 
tion incidents. Four patients had evidence of angiographic 
restenosis. The MLD (mm) and percent stenosis were 0.77 _-2- 
0.27/72.5 • 8.6 pre angioplasty, 2.08 _+ 0.4/25.7 • 9.8 post angio- 
plasty and radiation and 2.05 • 0.59/25.7 _+_ 19.8 at follow-up 
respectively. 
Conclusion: Beta radiation can be feasibly and safely deliver- 
ed post coronary angioplasty witb a very encouraging reduc- 
tion 017 restenosis. 
Wirksamkeil der Be|astrahlung zur Priivenfion der Reslenose nach PTCA: Ein Zwischenbericht der BERT-StudŸ 
Zusammenfassung: "lu gr6Berer Fortschritte bleibt die 
Restenose die entscheidende Limitalion der PTCA. Kª 
dmchgefª Studien haben gezeigt, dal3 ionisiere nde Strah- 
len das AusmaB dieses Problems bcgrenzen k6nnen. Gam- 
mastrablung ist zur Reduktion der Instemrestenose auch bei 
Patienten effektiv, fª Bctastrahlen gibt es sowohl in Tieruw 
tmsuchungen als auch bei Patiertten ermutigende Ergebnisse. 
Das Ziel dieser Studie war festzustellen, ob die Verwendung 
eines nicht zeatricrten 5 F-Katheters zur Verabreichung ron 
betastrahlendcn Zylindern einen Effekt auf die Restenose 
nach PTCA aufweist. 
Ira AnschluB ah eine erfolgreiche PTCA wurden die Patien- 
ten zur Behandlung mJt 12, 14 oder 16 Gy randomisiert. 
Zw6tf betastrahlende Zylinder {,,seeds") mit 9~ wurden 
ª cine L~inge von 3 cm appIiziert, um die PTCA-Stelle 
abzudecken. Die Kontrollangiographie erfolgte nach sechs 
Monaten. Die Auswertung der Ausgangs- und Kontrotlangio- 
gramme wurde entsprechend eines doppelblinden Protokolts 
durchgeftihrt. 
Dieser Zwischenbericht umfaBt die ersten 35 Patienten, bei 
denen die Sechs-Monats-Kontrollangiographie durchgefª 
wurde. Es gab keine gr013eren Strahlenunf91 Bei vier Patien- 
ten kam es zu einer angiographisch definierten Restenose. Der 
minimale Lumendurchmesser (MLD) betrug 0,77 +- 0,27 mm 
und die Durchmesserstenose 72,5 + 8,6% (vor ffFCA), 2,08 ~: 
{1,4 mm und 25,7 • 9,8% nach PTCA und Bestrahlung sowie 
2,05 • 0,59 mm und 25,7 _+ 19,8% bei Kontrollangiographie. 
Schlul3folgerung: Eine Betabestrahlung kann einfach und 
sicher nach PTCA durchgefª werden, die Ergebnisse zur 
Verhinderung der Restenose sind ermutigend. 
Schliisseiw6rter: Betast~ahtung - Restenose 9PTCA 
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T he application of intracoronary brachytherapy to the problem of post angioplasty restenosis repre- 
sents a potential solution to what remains avexing prob- 
lem. Progress in refinement oftechnology and improve- 
ment of techniques have allowed interventional 
cardiologists to tackle increasingty challenging situa- 
tions successfully. In spite of this, the multiple attempts 
to limit the problem of restenosis have met with consis- 
tent disappointment [7]. Following numerous encourag- 
ing animal studies [1, 15-17], intracoronary gamma 
radiation has recentIy been demonstrated to be feasible 
in humans [3] and in a small, randomized trial to limit 
the problem of in-stent restenosis [13]. Although numer- 
ous beta radiation emitting systems have been used in 
animal studies, only a single system of a baUoon center- 
ed 90-yttrium (o0y) wire for post angioplasty use, has 
been reported in humans in a small feasibility trial [14]. 
The objective of the Beta Energy Restenosis Trial 
(BERT) was to assess the fe.asibility and safety of 3 pre- 
scribed oses of beta radiation delivered post angiopla- 
sty to the coronary artery by means of a non-ccntered 5 
French (F) catheter-based system for reducing resteno- 
sis in non-stented coronary arteries, and to determine 
its effect on the restenosis process. 
Methods 
In this interim analysis of the multicenter randomized 
open trial, 14 patients were recruited at Emory Univer- 
sity Hospital, 6 at Rhode Island Hospital and 16 at the 
Institut de Cardiologie de Montreal. 
The protocol was approved by the institutional review 
board of each participating institution. Written infor- 
med consent was obtained from each patient prior to 
enrolhnent and randomization i  the trial. 
Selection of Patients 
Patients aged between 18 and 80 years with angina of 
proven ischemia on laboratory testing due to undergo 
planned balloon angioplasty treatment of a single coro- 
nary lesion in a native coronary artery, were eligible for 
inclusion in the study. The target lesions were required 
to llave between 60 and 99% diameter stenosis. 
Patients were excluded for 1. evidence of a myocardial 
infarction within the 3 days p¡ to the procedure, 2. 
contraindication to aspirin, 3. left ventricu[ar ejection 
fraction less than 40%, 4. serum creatinine greater than 
2.0, 5. anticipated difficulty with follow-up, 6. tire threat- 
ening coexisting illness, 7. women of child bearing pote n- 
tial, 8. severe peripheral vascular disease, 9. unprotected 
left main coronary artery disease, 10. presence of throm- 
bus, 11. past chest radiotherapy, 12. lesion angled > 45 
degrees, 13. intraprocedural ngiographic evidence of 
thrombus, pasm of dissection, 14. unsatisfactory PTCA 
result requiring stent implantation. 
Procedure 
The patients were treated with 325 mg of aspirin, intra- 
venous nitroglycerin and heparin in doses adequate to 
maimain ah activated clotting time of at least 300 
seconds throughout the procedure. Baseline coronary 
angiography was performed and followed by YFCA 
according to standard clinical practice. Fifteen minutes 
after a successful trfCA, as determined by residual ste- 
nosis of < 50% and an increase of lumen diameter of 
> 20%, patients were randomized to receive 12, 14, or 
16 Gy as calculated at 2 mm from the center line. Pro- 
cedural success was determined by angiography. A 5 F 
delivery catheter (Novoste Corp, Norcross, Georgia) 
was positioned at the site of PTCA with 2 markers 
separated by 3 cm used for positioning of the catheter 
across the angioplasty site (I¡ 1). The guidewire 
was removed and a 3 cm long train of 90- 
strontium/yttrium (9~ seeds was positioned bet- 
ween the aforementioned markers using fluoroscopic 
visualization. The seeds remained in place for the peri- 
od determined to deliver the prescribed ose at 2 mm 
from the ]uminal center line without regard to any cur- 
vature of the source train (Figure 2). Following irradia- 
tion, angiography was repeated. Al1 cincangiograms 
were performed following intracoronary nitroglycerin. 
Two to 4 hours after the procedure the femoral sheaths 
were removed. Electrocardiograms were performed 
immediately and the next morning. Creatine kinase 
and MB fraction were measured prior to the procedure, 
at its completion and 8 and 16 hours post procedure. Ir
the procedure was uncomplicated, patients were 
diseharged the next day with instructions to continue 
325 mg aspirin indefinitely, and if a stent was implant- 
ed, ticlopidine 250 mg twice daily for 15 days. 
Radiation Details 
The radiation system used in this study consisted of a 
series of 12 independent cylindrical seeds delivered as a 
train in a non-centered delivew catheter. Each seed of 
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Figure 1. The Novoste TM Beta Cath system: transfer device attaehed 
to the 5 Fcatheter. 
Abbildung 1. Das Novoste TM BelaCath-System. Das Transport- 
geh~iuse und der 5 F-Katheter. 
2.5 mm length is composed of radioactive materials 
(90 SI q sintered into ceramic, sealed within a cylin- 
drical stainless teel capsule. The length of the source 
train chosen was calculated for t reatment over 30 mm, 
allowing for 5 mm proximal and distal to the angiopla- 
sty site when using a standard 20 mm balloon. The pre- 
scribed doses of 12, 14, and 16 Gy at 2 mm from the cen- 
ter of the catheter resulted in intracoronary dwell times 
of 158 to 218 seconds based on source activity and Gaf- 
Chromic Dosimetry Media measurements a previous- 
ly described [6]. The delivery system is a non-centered 
5 F device with potentiat for variation from the prescri- 
bed radiation dose to that del jvered to different sites of 
the arterial wall. The delivery catheter is non-occlusive 
in the target coronary vessel and therefore no dose 
fractionation is necessary of recommended.  
Quantitative Angiographic Analysis 
Angiography was performed in 2 orthogonal projec- 
tions pre and post angioplasty. These same views were 
repeated following radiation therapy and at follow-up. 
Decisions regarding inclusion and procedural  success 
were made using an online quantitative angiographic 
system. Atl procedural  and fol low-up angiograms were 
forwarded to the Emory University Angiographic Core 
Laboratory for interpretat ion and measurement by 
independent observers according to a previously vali- 
dated method [8] providing diameter  of the refercnce 
vessel and the minimal umen diameter  (MLD)  at base- 
Pre-Trcatment [:~ Cath. Post-Irradiation 6 In. F-U 
Figure 2 Right coronary arterv in RAO projection, pre treatment, with radioactive s eds in place, post treatment result and 6-month follow-up 
showing no evidente of rester, osis but some disease p~ ogr ssion i  ah asymptomatic patienl with negative funct[onal tests. 
Abbitdung 2. Rechte Koronararterie in RAO-Projektion, vor der Behandlª mit den plazierten radioaktiven Quellen, nach Behandlung und 
Kontrollangiographie nach sechs b Ionaten obne Anhalt f¨ Restenose bei geringer Progression. Der Patien{ war asymptomatisch, die nicbttnva- 
siven Befunde unauffallig. 
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line, post procedure and at follow-up. Acute gain (mm) 
was defined as MLD post angioplasty less the MLD pre 
angioplasty. Late loss was defined as MLD post angio- 
plasty less MLD at follow-up. Loss index was defined as 
late loss divided by the acute gain. Restenosis was de- 
fined as > 50% diameter stenosis at follow-up. 
Follow-Up 
Patients were contacted by telephone monthly. Clinical 
assessment was performed 3-monthly. Angiographic 
follow-up was performed at 6 months. Follow-up angio- 
graphy recorded less than 5 months after the procedure 
was excluded unless restenosis had occurred. 
]he  primary endpoint was the technical success of the 
irradiation treatment as defined by the ability to pass 
the closed end 5 F radiation catheter to the lesion site as 
verified by fluoroscopy and recorded on fihn, the ability 
to transfer the radiation source to the distal end of the 
delivery catheter and return it to the transfer device. 
Secondary clinical endpoints were death, myocardial 
infarction, coronary bypass urgery, target lesion revas- 
cularization and restenosis as defined by MLD < 50% 
at fotlow-up. 
Statistical A nalysis 
Alt values are provided as proportions o ras  mean +_ 
standard deviation. Comparisons of post procedural 
with 6-month follow-up results were done using the 
paired t-test. Statistical significance was indicated by p 
< 0.05 on a 2-tailed test, 
Results 
Of 43 patients recruited for inclusion in the study be- 
tween January 1996 and April 1997. Five patients were 
excluded following unsatisfactory results with angioplas- 
tv alone, requiring stent lmptantation. Thirty-eight 
underwent randomization for radiation therapy. One 
patient was unavailable for follow-up and therefore was 
excluded from this interim analysis. The radiation cathe- 
ter and seeds were deployed and the prescfibed ose 
delivered to all but 2 patients. In 1 patient, due to severe 
vascular tortuosity, the detivery catheter could not be 
advanced to the lesion site. In the other, due to obstruc- 
tion of the delivery catheter the radioactive seeds could 
not be transferred in the catheter. The patients' baseline 
clinical characteristics ate shown in Table 1. 
Procedure and Early Clinical Outcome 
This interim analysis includes the first 35 patients who 
underwent successful angioplasty, radiation therapy 
and 6-month follow-up (Table 2). 
The radiation therapy was well tolerated by all the pa- 
tients with no major complications during the treat- 
ments. None of the treatments required fractionation 
nor were they interrupted prematurely. In a single pati- 
Patients (n) 35 
Age (y) 58.0 (34--80) 
Diabetes (%) 4 (11) 
Hyperlipidemia (%) 15 (42.9) 
Hypertension (%) 11 (31.5) 
Smoker 25 (71.4) 
Table t. Patient baseline clinical characteristics. 
Tabetle 1. Klinische Ausgangswerte d r Patienten. 
Patients in) 35 






LVEF 56 • 8,8 (40-76) 
Lesion type A(%) O (17.1/ 
B1(%) 9(25.7) 
B2 (%) t8 (5L5) 
C (%) 2 (5.7) 
None (%) 26 (74.3) 
Mild (%) 6 (17.1) 
Moderate (%) 2 (5.7) 
Se~,ere (%) 1 (2.9) 
Calcification 
(.,)CA Pre treatment Post treatmenl 
MLD (mm) 0.77 +_. 0.27 2.08 +- 0.40 
RD (mm) 2.78 :_~: 0.39 2.80 _+ 0.40 
Stenosis (%) 72.5 • 8.6 25.7 • 9.8
Aeute gain (mm) I..31 • 0.39 
Table 2. Basc.tine and post treatment angiographic characteristics 
(LAD = left anterior descending; LCx = left cireumflex; RCA = right 
coronary artery; LVEF = left ventricular ejection fraction; OCA = 
quantitative coronary angiography; MLD =- minimat luminat diame- 
ter: RD = re[erence vessel diameter; acute gain = MLD post treat- 
ment minus M LI) pre treatment). 
Tabelle 2. Angiographische Charakte~istika vor und nach Behand- 
lung (LAD = Ramus interventricu/aris anterior; LCx = Ramus eir- 
cumflexus; RCA = rechte Koronararterie: LVEF = linksventrikul91 
Auswurffraktion; QCA = quantitative Koronarangiographie; MLD 
= minimaler Lumendurchmesser; RD .-: Durchmesser des Referenz- 
gef~i6es; acute gain = MLD nach PTCA minus MLD vor PTCA). 
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ent, due to severe catcification, the deIivery catheter 
could not cover the entire lesion. In another patient, fol- 
lowing overtightening of the Tuohy-Borst valve, a kink 
in the hydrautic system used for seed deployment, pre- 
vented the return of the seeds to the protš housing. 
The entire system was immediately removed and deposi- 
red into the awaiting Lucite radioprotective box with no 
increased radiation exposure. In a further patient the 
distal gold marker was not retrieved into the protective 
housing at the completion of the procedure. Al1 the 
radioactive seeds, however, were safely in the radiopro- 
tective housing. There were no acute radiation events. 
Following angioplasty and radiation therapy 3 patients 
suffered acute vessel closure, requiring re-PTCA and 
stent implantation. Two further patients required stent 
implantation due to worsening of di ssections that were 
present post PTCA but pre-radiation therapy. 
Clinical and Angiographic Fotlow- Up 
~lhe MLD (mm) and percent stenosis were 0.77 • 
0.27/72.5 _+ 8.6 pre angioplasty, 2.08 _+ 0.4/25.7 • 9.8 post 
angioplasty and radiation and 2.05 _+ 0.59/25.7 _+ 19.8 at 
follow-up respectively (Table 3). 
Four of the 35 patient, cohort presented with angiogra- 
phic restenosis at the treated site. PTCA was perfor-. 
med in 1 case for angiographic restenosis at the sarne 
site. Two patients underwent coronary artery bypass 
surgery, one at 4 months although the target lesion had 
been stented and was patent. 
Of the 5 patients treated with stents initially none 
showed angiographic restenosis, the patients with 
angiographic restenosis were from the non-stented 
cohort. 
Post treatment 6-month Iollow-up 
MLD (mm) 2.08 _+ 0.40 2.05 _+ 0.59* 
RD (mm) 2.80 _+ 0.40 2.77 +_ 0 35* 
Stenosis (%) 25.7 _+ 9.8 25.7 _+ 19.8" 
Late loss (mm) 0.03 _+ 0 57 
Loss index -0.03 -+ 0.52 
Restenosis (%) 4/35 (11.4) 
Table 3. Angiographic results at 6 months (*p = not signfficant; MLD 
= minimal tuminal diameter; RD =reference diameter; Late loss -- 
MLD immediately post treatment minus MLD at follow-up; Loss 
index - luminal loss [over 6 months] divided by the acute angioplasty 
gain). 
TabelIe 3. Angiograpbische Ergebnisse nach sechs Monaten. 
There were no deaths of myocardial infarctions. No 
aneurysms were detected angiographically. 
Discussion 
The introduction of intracoronary brachytherapy asa 
potential solution for restenosis has led to encourage- 
ment in an otherwise disappointing field. Following 
probucol [11], i t i s  only the second treatment hat 
appears to reduce the post PTCA restenosis tate, and 
as opposed to probucol, it requires no pretreatment. 
Gamma and beta radiation have been shown to be 
effective in reducing the proliferative component  of 
stenosis in the animal overstretch balloon injury 
model, and have been demonstrated to be feasiblv 
de[ivered in humans. A recent randomized controlled 
trial demonstrated the effectiveness of gamma radia- 
tion in reducing in-stent restenosis at 6 months [13t. 
The single published trial using beta radiation demon- 
strated feasibility of the approach using a baltoon cen- 
tered 90y wire, however, restenosis occurred in 6 of 15 
patients [14]. 
This interim report of the multicenter BERT study 
demonstrates the feasibility and short4erm safety of 
applying beta radiation using a non-centered 5 F 
delivery catbeter, for the prevention of restenosis. In 
spite of 2 minor catheter incidents, no serious radiati- 
on events occurred in the short to medium term. The 
maintenance of the acute gain over the follow-up 
period, with minimal late loss anda  relatively Iow 
angiographic restenosis rate ate indicative of the 
potential for this technique and dispel some of the 
reservations regarding the effectiveness of beta 
radiation due to its redª penetrance and to the 
treatment iming [12 I. This is supported by the low 
requirement for target l esion and vessel revascu]a- 
rization. 
The theoretical concern of radiation catheter edge 
restenosis due to lower doses causing increased prolife- 
ration was not manifest in this study. At the prescribed 
doses no aneurysms were evident as have been report- 
ed with the use of a non-centered gamma radiation 
system ª higher doses [3]. 
The 9~ isotope combination with its prolonged hall 
life of 28 years [6], allows for the use of the same 
source seeds over a prolonged period and limits the 
alnount of source transfers required resulting in an 
overall decreased personnel radiation risk. 
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Limitations of the Smdy 
This study represents an interim report of the larger 
BERT feasibility study and therefore is not powered 
adequately to provide significant results regarding 
restenosis and revascularization requirement. I  is also 
a non-controlled study limiting the application of the 
restenosis results. The follow-up provides important 
data regarding short to intermediate t rm complica- 
tions, however, this must be viewed in the light that sig- 
nificantly higher doses of radiation applied to larger tis- 
sª arcas, when used for treatment of neoplasms, 
resulted in ah increased risk of coronary artery disease 
over the much longer term of 5 to 20 years [41. In spite 
of this, the safety of brachytherapy when used for kelo- 
id [2, 9] and heterotopic bone formation [5] has been 
confirmed for periods of longer than 20 years and furth- 
ermore the safety of peripheral vascular brachytherapy 
has been demonstrated during a 6-year follow-up peri- 
od [m], 
Conclusion 
This interim analysis of the BERT smdy demonstrates 
the feasibility and short and medium term safety of this 
non-centered 5 F device for delivering beta radiation to 
the vessel wall post angioplasty. Larger randomized and 
longer term studies ate required to provide the power to 
conclusively demonstrate hat beta radiation is effective 
in safely reduciug restenosis post angioplasty. 
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